Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 8:40 AM EDTCompany ParticipantsWilliam Meury - CEO ...
Incyte has struck a deal to buy a Star Therapeutics subsidiary for $1.25 billion upfront. The takeover, the biggest bet of ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The deal continues CEO Bill ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Incyte shares were up Thursday after the drugmaker announced Bill Meury would replace the retiring Hervé Hoppenot as CEO. Hoppenot is retiring effective immediately after 11 years leading the firm.
Hosted on MSN
Incyte CEO Shake-Up Sparks M&A Buzz As RBC Analyst Highlights Meury’s Track Record: Retail Is All In
RBC Capital Markets said investors may view Incyte’s CEO change as a potential prelude to strategic moves or M&A activity, citing new chief executive Bill Meury’s track record of leading companies ...
CEO Bill Meury puts his stamp on Incyte with swift changes to operations, leadership and real estate
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 3 min While he understands the company ...
Clinical stage biopharma firm Karuna Therapeutics has named Bill Meury president and CEO, a move effective on January 3. He succeeds Dr. Steve Paul, who is transitioning to chief scientific officer ...
Bill Meury, president and CEO of Karuna Therapeutics, speaks with WebMD Chief Medical Officer John Whyte, MD, about the differences in drug development in psychiatry and the importance of innovation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results